Trial Spotlight: Shaji Kumar on the EQUATE Study for Newly Diagnosed Multiple Myeloma – News from the ECOG-ACRIN Cancer Research Group

The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients

Read the full article here

Related Articles